Corporate Legal Counsel

Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon's drug candidates, referred to as patient responders. The name Acrivon (derived from Greek for "accurate") embodies how our OncoSignature tests link the patient's active tumor-driving mechanisms with the drug's mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations.
Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received fast track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon's ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs, consisting of its development candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and additional programs targeting these two critical nodes in the DNA Damage Response, or DDR, pathways.
Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.
Position Overview:
The Corporate Legal Counsel will be a key member of Acrivon Therapeutics' Legal and IP Team. This position will be based in Watertown, MA.
We are seeking an experienced and driven Legal Counsel who thrives in a fast-paced, high-performance, and collaborative environment to join our team. The ideal candidate has in-house experience, with a bio/pharmaceutical company strongly preferred. This individual must have sufficient experience handling contracts, from drafting through final negotiation, and will be responsible for providing Legal Counsel in support of our clinical, operations, and compliance efforts. Candidates with securities experience strongly preferred. This position will report to the Chief Legal Officer.
Duties and Responsibilities:

• Serve as Legal Counsel in designated areas of responsibility based on experience and expertise (ex: clinical trials, healthcare compliance, privacy, commercial contracting, etc.).
• Provide advice and education on legal topics pertinent to role, based on areas of expertise and responsibility.
• Responsible for maintaining an understanding and awareness of all relevant and current laws, developments, and practices.
• Independently draft, negotiate and/or provide oversight in the execution of various agreements.
• Review documents for compliance with laws and regulations, including informed consents.
• Assist in handling privacy related matters.
• Collaborate and/or provide legal and compliance training to clients as applicable to role and engage in cross-training with other members of team.
• Lead the annual review of corporate policies; train the company on Code of Business Conduct, Insider Trading and other corporate compliance policies.
• Assist in preparation of corporate filings for both SEC/NASDAQ. Collaborate with Finance with all matters relating to the annual shareholder meeting, proxy preparation, meeting details.
• Lead key support for Finance on all matters relating to the review of quarterly and annual filings.
• Working with the CLO, support Investor Relations in review of materials directed to investors, press releases.
• Partner with Finance in the preparation of materials for Audit Committee; assist with all requests from external and internal auditors (independence, quarterly legal letters, minutes, and audit reviews).
• Oversee the state-by-state compliance in the US as company expands/hires employees in the state; set up CT corporation and very other corporate obligations.
• Complete special projects as requested.

Qualifications:

• JD from an accredited law school and admitted to practice in Massachusetts or other U.S. state is required.
• A minimum of 5 years of relevant experience in-house or with a top-tier law firm, within high-growth, public, biotechnology or pharmaceutical companies preferred.
• A minimum of 5 years of experience drafting, negotiating, and executing contracts is required.
• Knowledge of the biopharmaceutical clinical development process, including the conduct of clinical trials and regulatory requirements is preferred.
• Experience with clinical trials, supply and manufacturing arrangements, and/or privacy compliance preferred.
• Experience with providing practical legal, compliance, and/or business advice as appropriate is required.
• Track record of working as a "team player" to support departmental success and foster a collaborative environment.
• Experienced with contract management tools and technology, including LinkSquares.
• Excellent research, writing, and communication skills required.
• Redlining skills with strong attention to detail.
• Strong working knowledge of technical tools, including Word, Excel, PowerPoint, Microsoft Teams, and document sharing and e-signing tools is required.
• Extensive knowledge of relevant laws, regulations, guidance, and industry codes.

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.